Managing the acute psychotic episode

British Medical Journal

Volumn 334, Issue 7595, 2007, Pages 686-692

  Byrne, Peter ^a  

^a Early Intervention Team for Ealing   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHINESE DRUG; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PIMOZIDE; PLACEBO; QUETIAPINE; RISPERIDONE; SULPIRIDE; TRIFLUOPERAZINE; ZOTEPINE; ZUCLOPENTHIXOL ACETATE;

BEHAVIOR THERAPY; CLINICAL FEATURE; COGNITIVE THERAPY; DIAGNOSTIC APPROACH ROUTE; DIFFERENTIAL DIAGNOSIS; EXTRAPYRAMIDAL SYMPTOM; HEART DISEASE; HUMAN; LABORATORY TEST; MINI MENTAL STATE EXAMINATION; PATIENT ATTITUDE; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PSYCHOEDUCATION; PSYCHOSIS; RELAPSE; REVIEW; SEDATION; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; ACUTE DISEASE; ANAMNESIS; MENTAL HEALTH; METHODOLOGY; PATIENT REFERRAL; PSYCHOTHERAPY; RECURRENT DISEASE; TREATMENT OUTCOME;

ACUTE DISEASE; ANTIPSYCHOTIC AGENTS; DIAGNOSIS, DIFFERENTIAL; HUMANS; MEDICAL HISTORY TAKING; MENTAL STATUS SCHEDULE; PSYCHOTHERAPY; PSYCHOTIC DISORDERS; RECURRENCE; REFERRAL AND CONSULTATION; TREATMENT OUTCOME;

EID: 34247192606     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.39148.668160.80     Document Type: Review

References (26)

1. Brugha T, Singleton N, Meltzer H, Bebbington P, Farrell M, Jenkins R, et al. Psychosis in the community and in prisons: a report from the British national survey of psychiatric morbidity. Am J Psychiatry 2005;162:774-80.
2. Ostling S, Skoog I. Psychotic symptoms and paranoid ideation in a nondemented population-based sample of the very old. Arch Gen Psychiatry 2002;59:53-9.
3. Boydell J, van Os J, McKenzie K, Murray RM. The association of inequality with the incidence of schizophrenia: an ecological study. Soc Psychiatry Psychiatr Epidemiol 2004;39:597-9.
4. Müeller-Oerlinghausen B, Berghöfer A, Bauer M. Bipolar disorder. Lancet 2002;359:241-7.
5. Henquet C, Krabbendam L, Spauwen J, Kaplan C, Lieb R, Wittchen HU, et al. Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. BMJ 2005;330:11.
6. Read J, Haslam N, Sayce L, Davies E. Prejudice and schizophrenia: a review of the "mental illness is an illness like any other" approach. Acta Psychiatr Scand 2006;114:303-18.
7. Harrison G, Hopper K, Craig T, Laska E, Siegal C, Wanderling J, et al. Recovery from psychotic illness: a 15- and 25-year follow-up study. Br J Psychiatry 2001;178:506-17.
8. Sachdev P. Schizophrenia-like psychosis and epilepsy: the status of the association. Am J Psychiatry 1998;155:325-36.
9. Lieberman JA, Tollefson GD, Charles C, Zipursky R, Sharma T, Kahn RS, et al. Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch Gen Psychiatry 2005;62:361-70.
10. Taylor D, Paton C, Kerwin RW. The Maudsley 2005-2006 prescribing guidelines. 8th ed. London: Taylor and Francis, 2005.
11. Hale AS. ABC of mental health: depression. BMJ 1997;315:43-6.
12. Singh SP, Croudace T, Amin S, Medley I, Jones PB, Harrison G. Three-year outcome of first-episode psychoses in an established community psychiatric service. Br J Psychiatry 2000;176:210-6.
13. Edwards J, Harris MG, Bapat S. Developing services for first-episode psychosis and the critical period. Br J Psychiatry 2005;187:s91-7.
14. McCreadie RG. Diet, smoking and cardiovascular risk in people with schizophrenia: descriptive study. Br J Psychiatry 2003;183:534-9.
15. Khunti K, Davies M. Metabolic syndrome. BMJ 2005;331:1153-4.
16. Tyrer P, Bajaj P. Nidotherapy: making the environment do the therapeutic work. Adv Psychiatr Treat 2005;11:232-8.
17. Penn DL, Waldheter EJ, Perkins DO, Mueser KT, Lieberman JA. Psychosocial treatment for first-episode psychosis: a research update. Am J Psychiatry 2005;162:2220.
18. Kingdon DG, Turkington D. Cognitive therapy of schizophrenia. New York: Guildford Press, 2005.
19. Lambert M, Conus P, Wade D, Yuan H, Moriz S. The impact of substance use disorders on clinical outcome in 643 patients with first-episode psychosis. Acta Psychiatr Scand 2005;112:114-8.
20. Hogarty GE, Ulrich U. The limitations of antipsychotic medication on schizophrenia relapse and adjustment and the contributions of psychosocial treatment. J Psychiatr Res 1988;32:243-50.
21. Petersen L, Jeppesen P, Thorup A, Abel MB, Ohlenschlaeger J, Christensen TO, et al. A randomised multicentre trial of integrated versus standard treatment for patients with a first episode of psychotic illness. BMJ 2005;331:602.
22. Larsen TK, Melle I, Auestad B, Friis S, Haahr U, Johannessen JO, et al. Early detection of first-episode psychosis: the effect on 1-year outcome. Schizophr Bull 2006;32:758-64.
23. Garety PA, Craig T, Dunn G, Fornells-Ambrojo M, Colbert S, Rahaman N, et al. Specialised care for early psychosis: symptoms, social functioning and patient satisfaction: randomised controlled trial. Br J Psychiatry 2006;188:37-45.
24. Nordentoft M, Laursen TM, Agerbo E, Qin P, Hoyer EH, Mortensen PB. Change in suicide rates for patients with schizophrenia in Denmark, 1981-97: nested case-control study. BMJ 2004;329:261.
25. Bertlote J, McGorry PD. Early intervention and recovery for young people with early psychosis: consensus statement. Br J Psychiatry 2005;187:s116-9.
26. Kerwin RW, Bolonna A. Management of clozapine-resistant schizophrenia. Adv Psychiatr Treat 2005;11:101-6.